ACIU Nov 2024 2.500 call
| Previous close | 1.3800 |
| Open | 1.3000 |
| Bid | 0.0000 |
| Ask | 2.8500 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 44 |
Simply Wall St.Individual investors own 24% of AC Immune SA (NASDAQ:ACIU) shares but private equity firms control 30% of the company
Key Insights The considerable ownership by private equity firms in AC Immune indicates that they collectively have a...
GlobeNewswireAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapyACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunothe
- GlobeNewswire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC
